Leading Pharmaceutical Innovation

1. Front Matter

   Pages i-xv

   PDF

2. Innovation: Key to Success in the Pharmaceutical Industry

   • Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer

   Pages 1-16

3. The Industry Challenge: Who Would Want to Be in This Business?

   • Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer

   Pages 17-39

4. The Science and Technology Challenge: How to Find New Drugs

   • Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer

   Pages 41-61

5. The Pipeline Challenge: How to Organize Innovation

   • Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer

   Pages 63-78

6. The Make-or-Buy Challenge: How to In- and Outsource Innovation

   • Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer

   Pages 79-110

7. The Open Innovation Challenge: How to Partner for Innovation

   • Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer

   Pages 111-133

8. The Internationalization Challenge: Where to Access Innovation

   • Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer

   Pages 135-153

9. Future Directions and Trends

   • Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer

   Pages 155-163

10. Back Matter

    Pages 165-179

    PDF

This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management methods in the drug development pipeline; new technologies as enablers for cutting-edge R&D; and new forms of cooperation and internationalization, such as open innovation in the early phases of R&D. New models and methods are illustrated with cases from Europe, the US, and Asia. This third fully revised edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation.

• Pharmaceutical industry
• Pharmaceuticals
• Pharmacoeconomics
• Drug discovery
• Innovation
• R&D
• Innovation management
• R&D Management
• Science and technology
• Globalization

“Health care innovation is possibly the greatest opportunity and challenge of our generation. This important book shows how pharmaceutical companies will continue to play an instrument role in making our lives better.” (Stefan Thomke, William Barclay Harding Professor of Business Administration, Harvard Business School)

“Very comprehensive review and analysis of current challenges for the biopharmaceutical industry. To stay competitive in this new technology driven environment, the industry started to develop new partnership models to close the innovation gap and provide patients with the relevant healthcare toolkits at the convergence of pharmaceuticals, diagnostics and IT technologies. Very exciting times ahead well depicted in this book!” (Karima Boubekeur, VP Emerging Portfolio and Search & Evaluation, AstraZeneca)

“Great. The 3rd edition is not only an update. It’s an outstandingly featured summary on the challenges of pharma innovation.” (Eckard von Keutz, SVP and Headof Early Development, Bayer Healthcare)

“…a profoundly researched and comprehensively illustrated creation of the value-drivers of pharmaceutical innovation.” (Florian Gantner, VP Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim)

“’Leading Pharmaceutical Innovation’ is the benchmark on pharmaceutical innovation management.” (Alexander Musil, CFO Takeda Mexico)

“Globalization, internationalization and open innovation are three major trends in the industry. Gassmann, Schuhmacher, von Zedtwitz and Reepmeyer provide most valuable insights in these topics. I highly recommend reading this book.” (Mathias Schmidt, CEO Armagen)

“I recommend this new book to pharma managers and researchers in this industry.” (Maximilian von Wuelfing, General Manager Mylan BeLux)

“This text is an excellent information source for innovation concepts in the modern era when pharma productivity is getting ever challenging in this global environment.” (Praveen Tyle, Executive Vice President R&D, Lexicon Pharmaceuticals)

“The book remains the key important publication of pharmaceutical innovation for business executives, scientists and students. The 3rd edition was updated especially regarding innovation alliances and addresses the key challenges that pharmaceutical R&D is facing nowadays.” (Katharina Caspary, Director Pharmacovigilance, Horizon Pharma)

“Excellent book for strategies on the management of pharma innovation. Highly recommendable for creating the bigger picture and new perspectives for action.” (Ingo Gaida, Head of IT Operations R&D, Bayer Business Services)

“Analytical & critical - a "spot on" review of the constantly changing pharma environment.” (Guenther Forster, former SVP Medical Development & Strategies, MerckSerono)

“This great book helps to understand the complexity of the challenges the pharmaceutical industry is facing.” (Ingo Henes, SVP Human Relations at Rentschler Biotechnologie)

• Institute of Technology Management, University of St. Gallen, St. Gallen, Switzerland

  Oliver Gassmann

• Faculty of Applied Chemistry, Reutlingen University, Reutlingen, Germany

  Alexander Schuhmacher

• Department of Strategic Management, Kaunas University of Technology, Kaunas, Lithuania

  Max von Zedtwitz

• Novi, USA

  Gerrit Reepmeyer

Prof. Dr. Oliver Gassmann is professor of technology management at the University of St. Gallen (Switzerland), and managing director of the Institute of Technology Management. After completing his PhD in 1996, he was head of corporate research at Schindler. He published over 400 papers in leading international management journals. In 2014, he was awarded the Scholary Impact Award by the Journal of Management, and in 2015 with the Citation Excellence Award of the Emerald Group. He also serves as a founder and advisor on several boards.

Prof. Dr. Alexander Schuhmacher is professor at Reutlingen University (Germany). He teaches in business management and medical science. He officiates as Senator of Reutlingen University and he also serves as managing director of the Knowledge Foundation @ Reutlingen University. He worked for 14 years in various R&D positions in the pharmaceutical industry. As member of Nycomed’s senior R&D management team, he headed the StrategicPlanning & Business Support function and co-headed the R&D integration team following the merger of Nycomed and ALTANA Pharma.

Prof. Dr. Max von Zedtwitz is professor at Kaunas University of Technology (Lithuania), and director of the GLORAD Center for Global R&D and Innovation. Previously he was a professor at Tsinghua, Peking University, Skoltech, and IMD, and a vice president at PRTM. In 2009 he was recognized by IAMOT as one of the fifty most influential innovation scholars worldwide. A frequent public speaker, he has appeared on television, and has been cited in the Economist, China Daily, the South China Morning Post and the New York Times.

Dr. Gerrit Reepmeyer is co-founder & COO of Guardhat Inc., a startup based in Detroit (USA). Prior to that, he held various executive leadership positions in industrial and technology companies. He started his career in management consulting with McKinsey & Company. He has a PhD degree from the University of St. Gallen and was a research scholar at Columbia University in New York. He co-authored several books and publications on technology management, and he is co-inventor of five patents.

Policies and ethics